Roth/MKM analyst Matt Koranda lowered the price target on Gentherm Incorporated (NASDAQ: THRM) to $39.00 (from $44.00) while maintaining a Buy rating.

The analyst commented, "We are incorporating Gentherm's recent results into our model while forecasting sales/adj EBITDA below the midpoint of 2026 guidance. We still see key positives to our constructive view: (1) healthy-enough outgrowth vs. auto production, (2) adjacent market growth traction, and (3) an improving margin set-up into 2027. However, given the Modine Performance Technologies combination (see here; should take most of 2026 to close), and recent macro disruption, we expect THRM stock could remain rangebound while investors await clarity. Our 2026/2027 estimates are little-changed. PT goes to $39 (from $44) to reflect peer multiple compression/macro risks."